Telix and SHINE partner for Lutetium-177 Supply
Telix announces a new global clinical supply agreement with Wisconsin-based SHINE Technologies, LLC (SHINE) for lutetium-177
Telix Expands Lutetium-177 Network with Eckert & Ziegler Clinical Supply Agreement
Telix announces a global clinical supply agreement with Eckert & Ziegler for lutetium-177
Japanese Prostate Cancer Imaging Trial Meets Study Objectives
Telix and Kanazawa University announce that the Phase I clinical study of TLX591-CDx for prostate cancer imaging in Japanese patients has met its objectives
Darren Smith Joins Telix as Deputy Group Chief Financial Officer
Telix is pleased to announce that Darren Smith has joined the Company as Deputy Group Chief Financial Officer.
Telix and Biokosmos Sign Distribution Agreement for Prostate Cancer Imaging in Greece and Cyprus
Telix signs a commercial distribution agreement with BIOKOSMOS for prostate cancer investigational imaging product Illuccix® in Greek and Cypriot markets.
First Patient Dosed in ProstACT Program for Prostate Cancer Therapy
Telix announces that the first patient has been dosed in the Company’s PSMA-targeting ‘ProstACT’ therapeutic program.
Telix Completes A$175 Million Placement and Launches A$25 Million SPP
Telix announces a successful $175 million institutional placement and launches Share Purchase Plan to raise up to $25 million.
Activities Report and Appendix 4C for December 2021 Quarter
Telix provides its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 31 December 2021.
Telix Collaborates with Olivia Newton-John Cancer Research Institute on Brain Cancer Imaging Study
Telix is pleased to announce a clinical data access agreement with the Olivia Newton-John Cancer Research Institute (ONJCRI) relating to a prospective clinical trial investigating the use of O-(2-[18F]fluoroethyl)-L-tyrosine or 18F-FET to image glioblastoma patients with positron emission tomography (PET) (FET-PET). 18F-FET is under development by Telix (referred to as TLX101-CDx) as a complementary diagnostic agent to its TLX101 glioblastoma therapeutic candidate.
First Patient Dosed in Study of Targeted Alpha Therapy Candidate for Bladder Cancer
Telix announces that a first patient has been dosed in the ‘PERTINENCE’ Phase I study of TLX250-CDx in patients with non-muscle-invasive bladder cancer